5th Mar 2007 08:36
ABCAM Plc05 March 2007 For immediate release 05 March 2007 ABCAM PLC ("Abcam" or "the Company") Shareholding Cambridge UK, 05 March 2007: Abcam plc announces that in accordance with theFSA's new Disclosure and Transparency Rules, the Company was notified on 22February that, as at 22 February 2007, Aviva plc had a direct and indirectinterest in voting rights over 2,275,940 ordinary shares of 1p each in theCompany amounting to approximately 6.58%of the issued share capital of theCompany. For further information please contact: Abcam + 44 (0) 1223 696000Jonathan Milner, Chief Executive OfficerEddie Powell, Chief Financial Officerwww.abcam.com Numis Securities + 44 (0) 20 7776 1500James Black Buchanan Communications + 44 (0) 20 7466 5000Mark Court / Mary-Jane Johnson Notes for editors: About Abcam plc Abcam is a producer and distributor of research-grade antibodies headquarteredin Cambridge, UK, with a US office located in Cambridge, Massachusetts. Abcamwas admitted to AIM in November 2005 and trades under the ticker symbol ABC.The Company produces and distributes its own and third party produced antibodiesto academic and commercial users throughout the world with product informationprovided and ordering available through the Company's website, www.abcam.com.The antibodies are sold under the Abcam brand name. The Company's vision is tobuild the largest online antibody resource in the world while also ensuring thatthe antibodies are of high quality and commercially viable. Abcam now has anonline catalogue of approximately 29,000 products, most of which are antibodies,from over 200 suppliers supported by up-to-date and detailed technical datasheets, which are created by the Company. The Company currently employs 120staff in its three operating companies. This information is provided by RNS The company news service from the London Stock ExchangeRelated Shares:
ABC.LAviva